Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

for the year ended December 31, 2010 were $37.8 million, compared to $48.0 million for the year ended December 31, 2009.  The decrease in R&D expenses was due primarily to a decrease in clinical and other project expenses to support the UDB Phase 3 clinical program, which was suspended in the third quarter of 2009, and a decrease in clinical and other project expenses to support the LEVADEX Phase 3 clinical program. The Company completed clinical development for LEVADEX in 2010 and plans to submit an NDA to the FDA in the first half of 2011. The decrease in R&D expenses was partially offset by an increase in personnel related expenses, including stock-based compensation.  

Sales, general and administrative (SG&A) expenses for the fourth quarter ended December 31, 2010 were $4.0 million compared to $3.3 million for the same period in 2009. The increase in SG&A expenses for the fourth quarter ended December 31, 2010 as compared to the same period in 2009 was related primarily to an increase in personnel related expenses, including stock-based compensation, and an increase in professional services and LEVADEX related marketing activities.

SG&A expenses for the year ended December 31, 2010 were $15.7 million compared to $13.1 million for the year ended December 31, 2009. The increase in SG&A expenses was due primarily to an increase in personnel related expenses, including stock-based compensation, an increase in professional services and LEVADEX related marketing activities and an increase in other expenses.For the fourth quarter and year ended December 31, 2010, non-cash stock-based compensation and depreciation was approximately $2.1 million and $7.8 million, respectively.

2011 Financial Outlook MAP Pharmaceuticals currently is working with its partner Allergan on planning activities for LEVADEX.  At the conclusion of this exercise, the Company will provide financial guidance for 2011.

About M
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... way of life at Meriter Hospital , a ... care to southern Wisconsin. Meriter includes a hospital, clinic, ... service. Formed from a merger of Madison General Hospital ... 430 active and associate physicians in over 30 medical ...
... from traditional paper phone bills to SBC eBill ... the "Save a StampHelp Save a Life" campaign, created in ... Inc. will contribute $1 dollar for every SBC customer that ... 15, 2004. , ,In 2004, an estimated 216,000 new cases ...
... Despite a two-year-plus economic recovery in the United States, ... which source you cite) have mysteriously failed to appear ... they not been created as expected? The list of ... recovery, uncertainty about the future, terrorism and the war ...
Cached Biology Technology:Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Gone missing: Today jobs, tomorrow workers? 2Gone missing: Today jobs, tomorrow workers? 3
(Date:7/30/2014)... (125I) in cancer treatment has been shown to ... critical for neural transmission between the peripheral and ... from Institute of Radiation Medicine, Chinese Academy of ... implanted into rat dorsal root ganglia (DRG) to ... different radioactivity (0, 14.8, 29.6 MBq) were implanted ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
(Date:7/30/2014)... SAN JOSE, Calif. , July 30, 2014 ... industry-academia partnership with the United States Air Force ... project proposed by Binghamton ... for human performance monitoring (HPM). The $425,000 project, ... and electronics packaging firm i3 Electronics, Inc. ( ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... life," but does today,s unprecedented level of dietary variety ... it might. According to ASN Spokesperson Shelley ... eating, itself- can trigger release of various brain chemicals, ... with drug addiction and withdrawal. And, as can happen ...
... Populations of spur-thighed tortoises ( Testudo graeca ), a species ... fires if outbreaks occur once every three decades or more. ... each fire. These are the results of a study by ... fire in the Sierra de la Carrasquilla mountains in Murcia ...
... is available in German . They live their lives ... upright position, sloths spend most of their lives hanging in trees ... slowly. Very slowly. But why are sloths so ,lazy,? And how ... lifestyle in the course of evolution? Zoologists of the Friedrich Schiller ...
Cached Biology News:Does food act physiologically like a 'drug of choice' for some? 2Tortoise populations can withstand fires every 30 years 2The decoding of slowness 2
... that has been shown to help maintain the ... by reverse transcription, in vitro RNA transcription, and ... tightly binds RNases in a 1:1 ratio. It ... as RNase A, RNase B, RNase C, and ...
...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
...
Biology Products: